Ameriprise Financial Inc Greenwich Life Sciences, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.77 - $12.3 $75,811 - $120,011	-9,757 Reduced 15.39%	53,647 $564,000
Q3 2023 Nov 14, 2023	SELL	$8.41 - $10.66 $40,267 - $51,040	-4,788 Reduced 7.02%	63,404 $560,000
Q2 2023 Aug 14, 2023	BUY	$9.58 - $13.2 $24,754 - $34,108	2,584 Added 3.94%	68,192 $657,000
Q1 2023 May 15, 2023	SELL	$12.12 - $20.8 $509 - $873	-42 Reduced 0.06%	65,608 $904,000
Q4 2022 Feb 14, 2023	BUY	$9.04 - $16.88 $35,698 - $66,659	3,949 Added 6.4%	65,650 $997,000
Q3 2022 Nov 14, 2022	BUY	$7.81 - $12.02 $152,451 - $234,630	19,520 Added 46.28%	61,701 $561,000
Q2 2022 Aug 15, 2022	SELL	$7.14 - $20.36 $3,755 - $10,709	-526 Reduced 1.23%	42,181 $359,000
Q1 2022 May 16, 2022	BUY	$16.3 - $24.65 $225,575 - $341,131	13,839 Added 47.94%	42,707 $837,000
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $491,101 - $889,895	22,569 Added 358.29%	28,868 $701,000
Q3 2021 Nov 15, 2021	BUY	$38.65 - $46.11 $243,456 - $290,446	6,299 New	6,299 $246,000

1.01M

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $173M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.